EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens

Alfredomaria Lurati, Antonella Laria, Paola Faggioli, Antonio Tamburello, Laura Castelnovo, Antonino Mazzone

Beyond Rheumatology · 2020

DOI: 10.4081/br.2020.34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Beyond Rheumatology, 2020. Verfasst von Alfredomaria Lurati und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bone marrow edema syndrome (BMES) is a severely disabling pain syndrome without a definite treatment and refers to transient clinical conditions with unknown pathogenic mechanism, such as transient osteoporosis of the hip, regional migratory osteoporosis, and reflex sympathetic dystrophy. Magnetic resonance imaging is used for early diagnosis and monitoring of its progression. Early differentiation from other aggressive conditions with longterm sequelae is essential in order to avoid unnecessary treatment. The aim of this monocentric trial was to test the efficacy and the safety of amino-bisphosphonate neridronate administered in two different regimens in patients with BMES. 192 patients with BMES secondary to osteoarthritis localized in the knee, hip, wrist or foot were randomly assigned to intravenous (iv) infusion of 100 mg neridronate given four times over 10 days (Group A, 72 subjects) or alternatively to iv infusions of 100 mg every 21 days over 3 months (Group B, 120 subjects). Magnetic resonance image (MRI) was performed at baseline and after 180 days. We assessed a 0-100 mm pain visual analogue scale (VAS) in each patient, too. Outcomes were MRI changes and VAS changes. A control group (35 patients) was enrolled too, treated conservatively with non-steroidal anti-inflammatory drugs and articular rest. We observed a significant improvement in MRI with the resolution of bone marrow lesions present at the baseline (P

Zitieren

APA

Lurati, A., Laria, A., Faggioli, P., Tamburello, A., Castelnovo, L., & Mazzone, A. (2020). Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens. Beyond Rheumatology. https://doi.org/10.4081/br.2020.34

Vancouver

Lurati A, Laria A, Faggioli P, Tamburello A, Castelnovo L, Mazzone A. Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens. Beyond Rheumatology. 2020. doi:10.4081/br.2020.34

BibTeX
@article{Lurati2020,
  author = {Lurati, Alfredomaria and Laria, Antonella and Faggioli, Paola and Tamburello, Antonio and Castelnovo, Laura and Mazzone, Antonino},
  title = {Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens},
  journal = {Beyond Rheumatology},
  year = {2020},
  doi = {10.4081/br.2020.34}
}
Kostenlos starten →